

8 May 2007

Galapagos completes final share issue for Inpharmatica acquisition

Mechelen, Belgium; 8 May 2007 – Galapagos NV (Euronext & LSE: GLPG) announced today that it has issued a final tranche of 113,378 new shares in relation to the Inpharmatica acquisition.

On 6 December 2006, Galapagos announced the acquisition of UK-based Inpharmatica Ltd. Under the acquisition agreement, the shareholders of Inpharmatica contributed their C Preference shares to the capital of Galapagos, in exchange for a maximum of 2,165,532 newly issued Galapagos shares. A first tranche of 623,582 Galapagos shares was issued to former Inpharmatica shareholders in December 2006 as consideration for the contribution of their shares. On 6 April 2007, a second tranche of 613,270 new Galapagos shares was issued and allocated to the former Inpharmatica shareholders as further consideration. On 7 May 2007, the third and last tranche of 113,378 Galapagos shares was issued and allocated to the former holders of Inpharmatica C Preference shares as final part of the consideration for the acquisition; these shares are expected to be admitted to trading on Euronext Brussels, Euronext Amsterdam, and AiM starting on 11 May 2007. All shares issued under the acquisition agreement are subject to a lock up agreement that will come to an end on 10 May 2007.

The final total consideration which Galapagos has paid for the Inpharmatica acquisition is therefore 1,350,230 shares, which is 815,302 fewer than the maximum agreed upon between Galapagos and Inpharmatica shareholders. The reduced consideration is a result of Inpharmatica not meeting a commercial milestone upon an agreed date, as set forth in the acquisition agreement.

As a result of this share issue, the number of Galapagos' shares outstanding as of 7 May 2007 is 20,592,766 shares, representing a book value for share capital of €111.873.435,47. All newly issued shares rank pari passu with Galapagos' existing shares.

Between the first supplement dated 30 March 2007 and today's supplement to the Prospectus 2006, Galapagos made the following announcements:

Galapagos achieved milestones totaling €3.2 million in osteoarthritis alliance with GlaxoSmithKline

On 30 March 2007, Galapagos announced that it reached two significant milestones in its multi-year drug discovery alliance with GlaxoSmithKline in osteoarthritis, triggering payments of €3.2 million from GSK.

Galapagos signed two new drug discovery collaborations with Ono Pharmaceuticals

On 16 April 2007, Galapagos announced that its BioFocus DPI service division signed two new collaborations with Ono Pharmaceutical Company Ltd. These collaborations build on the successful relationship between Ono and DPI, which began in 2004.

Galapagos signed agreement worth up to €6.3 million with United States Environmental Protection Agency

On 18 April 2007 Galapagos announced that its service division BioFocus DPI entered into a multi-year compound management agreement with the United States EPA. BioFocus DPI will

provide chemical procurement and compound management services as part of the EPA's ToxCast™ Program (Prioritization of Environmentally Relevant Chemicals). The contract covers a period of up to five years and has a total value of up to €6.3 million.

Galapagos and AstraZeneca entered new drug discovery collaboration

On 19 April 2007 Galapagos announced that its service division, BioFocus DPI, entered into a new drug discovery collaboration with AstraZeneca, a global pharmaceutical leader. This is the second program between the two companies under an agreement signed in August 2006. In this new collaboration, BioFocus DPI will perform medicinal chemistry, computational chemistry and supporting biology and ADMET services for an AstraZeneca drug discovery program. Total contract value for Galapagos is €620,000.

Availability of documents

This document constitutes a supplement to the Galapagos 2006 Prospectus. The English version of this supplement has been approved by BFIC on 8 May 2007. This supplement, together with the Galapagos Registration Document 2006, the Transaction Note 2006, the Summary, and the first supplement of 30 March 2007, constitutes the 2006 Prospectus for the admission to listing of new Galapagos shares.

The 2006 Prospectus is available online at www.glpj.com/investor/prospectus.htm. The electronic versions of Galapagos' 2006 Company report and Annual brochure (including consolidated and non-consolidated accounts) are available online in both Dutch and English at www.glpj.com/investor/financial_reports.htm. Printed versions of the reports can be requested by e-mail: ir@glpj.com, by phone: +32 15 34 29 00, and by fax: +32 15 34 29 01.

This supplement is published in English and Dutch. The English and the Dutch versions have equal value. Onno van de Stolpe assumes the responsibility for the translation of the English version of this supplement into Dutch.

The press releases referred to above are available online at www.glpj.com/news/press.htm.

About Galapagos

Galapagos (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA; London AiM: GLPG) is a drug discovery company with clinical and pre-clinical programs in bone and joint diseases, cachexia, and menopausal hot flashes. Its division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. BioFocus DPI also provides adenoviral reagents for rapid identification and validation of novel drug targets, compound libraries for drug screening as well as chemogenomics and ADMET¹ database products to select targets and compounds. Galapagos currently employs 450 people and operates facilities in eight countries, with global headquarters in Mechelen, Belgium. More information about Galapagos and BioFocus DPI can be found at www.glpj.com and www.biofocusdpi.com.

¹ ADMET is the acronym for Absorption, Distribution, Metabolism, Excretion, and Toxicity: Meeting parameters against these five criteria is critical to the success of a pharmaceutical compound as a drug.

CONTACT

Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com

This supplement to the Prospectus 2006 may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.